Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
An update of a phase I/II study of the VEGF receptor tyrosine kinase inhibitor vatalanib and gemcitabine in patients with advanced pancreatic cancer Kuo, T., Cabebe, E. C., Koong, A., NORTON, J. A., Kunz, P. L., Ford, J. M., KAISER, H. L., Rogers, J., Sikic, B. I., Fisher, G. A. AMER SOC CLINICAL ONCOLOGY. 2008
View details for Web of Science ID 000208457401374